Sign In
Buy QDEL
$13.60
+0.310 (+2.33%)
At Close: Jun 03, 2026
QuidelOrtho (QDEL) Reports Solid Preliminary Q1 Revenues
12:10pm, Monday, 17'th Apr 2023
QuidelOrtho's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued strength in its non-respiratory product sales.
QuidelOrtho (QDEL) Soars 5.0%: Is Further Upside Left in the Stock?
10:41am, Monday, 17'th Apr 2023
QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why QuidelOrtho Stock Popped by 5% on Friday
06:05am, Saturday, 15'th Apr 2023
The diagnostics specialist released preliminary first-quarter revenue figures. These easily beat the average analyst estimate.
3 Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio
01:44pm, Thursday, 23'rd Mar 2023
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
QuidelOrtho's (QDEL) Rapid Antigen Test Gets De Novo FDA Approval
02:30pm, Monday, 13'th Mar 2023
QuidelOrtho's (QDEL) receipt of the FDA's De Novo approval is expected to enable it to provide the test as an aid in the diagnosis of SARS-CoV-2 infections in symptomatic individuals.
QuidelOrtho to Participate in the Raymond James 44th Annual Institutional Investor Conference
02:01pm, Thursday, 02'nd Mar 2023
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-car
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
06:01am, Wednesday, 01'st Mar 2023
Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its combination at-home COVID-19 and a flu test
QuidelOrtho (QDEL) Q4 Earnings Top Estimates, Margins Down
01:33pm, Thursday, 16'th Feb 2023
QuidelOrtho (QDEL) reports robust overall top-line results in fourth-quarter 2022, despite disappointing segmental and geographical performances on a reported basis.
QuidelOrtho Corporation (QDEL) Q4 2022 Earnings Call Transcript
09:55pm, Wednesday, 15'th Feb 2023
QuidelOrtho Corporation (NASDAQ:QDEL ) Q4 2022 Earnings Conference Call February 15, 2023 5:00 PM ET Company Participants Bryan Brokmeier - Vice President, Investor Relations Doug Bryant - President a
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates
07:34pm, Wednesday, 15'th Feb 2023
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 25.71% and 0.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
QuidelOrtho: Robust Pipeline Of Labs Products Ahead
07:00am, Sunday, 29'th Jan 2023
We believe the company's superior performance relative to other top healthcare equipment competitors is highlighted by its highest growth in Q3 2022. Following its acquisition, we believe the company'
QuidelOrtho to Present at the J.P. Morgan Healthcare Conference
07:00am, Wednesday, 28'th Dec 2022
SAN DIEGO--( BUSINESS WIRE )--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinica
QuidelOrtho's (QDEL) Myocardial Infarction Test Cleared in Canada
11:17am, Tuesday, 20'th Dec 2022
QuidelOrtho's (QDEL) TriageTrue hsTnl Test is to be used to diagnose myocardial infarction following Health Canada's approval.
QuidelOrtho's (QDEL) Latest JV to Boost Footprint in China
03:02pm, Monday, 19'th Dec 2022
QuidelOrtho's (QDEL) new JV will likely translate into a faster time-to-market and a more compelling menu for VITROS assays in support of its growth strategy in China and beyond.
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
12:48pm, Thursday, 08'th Dec 2022
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
